Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
复制标题
SOX9 在肾细胞癌、膀胱癌和阴茎癌中的表达及临床意义。
DOI：
10.1159/000455145
复制
发表时间：
2017
影响因子：
2.4
通讯作者：
Zhong Wei-De
中科院分区：
文献类型：
--
作者：
Wan Yue-Ping;Xi Ming;He Hui-Chan;Wan Song;Hua Wei;Zen Zhao-Chang;Liu Yuan-Ling;Zhou Yu-Lin;Mo Ru-Jun;Zhuo Yang-Jia;Luo Hong-Wei;Jiang Fu-Neng;Zhong Wei-De
背景新的分子标记物是评估肿瘤进展和评价治疗效果的重要诊断工具。SOX 9是发育过程的关键调节因子，在各种肿瘤中过表达，如前列腺癌、乳腺癌和结肠直肠癌。然而，利用SOX 9作为其他泌尿系统癌症的生物标志物尚未调查。方法在本研究中，成对的患者组织微阵列进行了分析，通过免疫组化，和SOX 9蛋白表达定量的免疫反应评分在肾细胞癌（RCC），膀胱癌（BCa），和阴茎癌（PC）患者。SOX 9蛋白表达在RCC（p< 0.001）和BCa（p< 0.001）中显著上调，并且与患者的晚期病理分级（RCC：p= 0.023）和临床分期（RCC：p= 0.022和BCa：p= 0.046）显著相关。基于TCGA数据集中的mRNA水平，SOX 9在具有性别（p= 0.027）、晚期病理分级（p= 0.003）和晚期临床分期（p= 0.001）的RCC中上调。Kaplan-Meier生存曲线显示具有高SOX 9水平的RCC患者具有较短的生存期（p< 0.001）。SOX 9高表达是肾细胞癌患者的独立预后因素（hazardratio 0.056，95%confidence interval 0.607-1.184; p< 0.001）。结论SOX 9在肾细胞癌和膀胱癌的发生发展中起重要作用，可作为肾细胞癌的生物标志物。
BackgroundNovel molecular markers are important diagnostic tools for the assessment of cancer progression and evaluation of effectiveness of the treatment. SOX9, a key regulator of developmental processes, is overexpressed in various neoplasms, such as prostate, breast, and colorectal cancers. However, the utilization of SOX9 as a biomarker for other urological cancers has not yet been investigated.MethodsIn the present study, paired patient tissue microarrays were analyzed by immunohistochemistry, and the SOX9 protein expression was quantitated as immunoreactive scores in patients with renal cell carcinoma (RCC), bladder cancer (BCa), and penile cancer (PC).ResultsIn comparison with normal tissues, SOX9 protein expression was significantly upregulated in RCC (p< 0.001) and BCa (p< 0.001), and significantly correlated with the advanced pathological grade (RCC: p= 0.023) and clinical stage (RCC: p= 0.022 and BCa: p= 0.046) of patients. Based on the mRNA level in the TCGA dataset, SOX9 was upregulated in RCC with gender (p= 0.027), advanced pathological grade (p= 0.003) and advanced clinical stage (p= 0.001). Kaplan-Meier survival curves revealed that RCC patients with high SOX9 levels had shorter survival (p< 0.001). Further, high SOX9 expression was an independent prognostic factor for RCC patients (hazard ratio 0.056, 95% confidence interval 0.607-1.184; p< 0.001).ConclusionThese findings suggest that SOX9 may play an important role in tumor progression of RCC and BCa and it may be used as a biomarker of this malignancy.